As in the recent use of a dual-targeting strategy to target an epidermal growth factor receptor mutation in non-small-cell lung cancer patients by combining two individual drugs (i.e., afatinib and cetuximab), resulting in dramatic inhibition of tumor growth. This evidence concerns the gene EGFR and non-small cell lung carcinoma.